ATE267607T1 - Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten - Google Patents

Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten

Info

Publication number
ATE267607T1
ATE267607T1 AT95906686T AT95906686T ATE267607T1 AT E267607 T1 ATE267607 T1 AT E267607T1 AT 95906686 T AT95906686 T AT 95906686T AT 95906686 T AT95906686 T AT 95906686T AT E267607 T1 ATE267607 T1 AT E267607T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
ligands
prevention
treatment
production
Prior art date
Application number
AT95906686T
Other languages
English (en)
Inventor
Richard J Armitage
William C Fanslow Iii
Dan L Longo
William J Murphy
Original Assignee
Immunex Corp
Nat Inst Of Health As Represen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22628670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267607(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp, Nat Inst Of Health As Represen filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE267607T1 publication Critical patent/ATE267607T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95906686T 1993-12-23 1994-12-21 Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten ATE267607T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17266493A 1993-12-23 1993-12-23
PCT/US1994/014767 WO1995017202A1 (en) 1993-12-23 1994-12-21 Method of preventing or treating disease characterized by neoplastic cells expressing cd40

Publications (1)

Publication Number Publication Date
ATE267607T1 true ATE267607T1 (de) 2004-06-15

Family

ID=22628670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95906686T ATE267607T1 (de) 1993-12-23 1994-12-21 Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten

Country Status (13)

Country Link
US (1) US5674492A (de)
EP (1) EP0751781B1 (de)
JP (1) JPH09507074A (de)
AT (1) ATE267607T1 (de)
AU (1) AU680102B2 (de)
CA (1) CA2179196A1 (de)
DE (1) DE69433820T2 (de)
DK (1) DK0751781T3 (de)
ES (1) ES2222463T3 (de)
NO (1) NO320354B1 (de)
NZ (1) NZ278740A (de)
PT (1) PT751781E (de)
WO (1) WO1995017202A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6132978A (en) * 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
CA2277223A1 (en) * 1997-01-10 1998-07-16 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
KR20010020611A (ko) * 1997-07-01 2001-03-15 아테로제닉스, 인코포레이티드 항산화제에 의한 과증식질병 치료의 향상
EP1059932A1 (de) * 1997-12-19 2000-12-20 Immunex Corporation Methode zur verminderung der empfindlichkeit gegenüber hiv-infektionen
AU2114999A (en) * 1998-01-14 1999-08-02 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis of melanoma
US7338767B1 (en) 1998-01-14 2008-03-04 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis, prognosis and/or treatment of melanoma
US5965712A (en) * 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
ATE310806T1 (de) * 1998-09-29 2005-12-15 Uab Research Foundation Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen
CA2357035A1 (en) * 1998-12-29 2000-07-06 University Of Vermont And State Agricultural College Use of cd40 engagement to alter t cell receptor usage
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
KR20020072277A (ko) * 1999-11-08 2002-09-14 아이덱 파마슈티칼즈 코포레이션 항-ｃｄ20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-ｃｄ40ｌ 항체를 이용한 ｂ세포 악성종양의치료방법
MXPA02007473A (es) * 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DE60116075T4 (de) * 2000-04-25 2007-06-06 Immunex Corp., Thousand Oaks Behandlung von tumoren mit photodynamischer therapie
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
DK1680141T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP2312315A1 (de) 2005-05-18 2011-04-20 Novartis AG Verfahren zur Diagnose und Behandlung von Krankheiten mit einer autoimmunen und/oder entzündlichen Komponente
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
EP1945260B1 (de) 2005-11-01 2012-10-24 Novartis AG Verwendungen von anti-cd80-antikörpern
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
NO2699601T3 (de) 2011-04-21 2018-06-16
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CA2888763A1 (en) * 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
JP6820565B2 (ja) * 2016-04-27 2021-01-27 国立大学法人大阪大学 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0897983T3 (da) * 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment

Also Published As

Publication number Publication date
US5674492A (en) 1997-10-07
DE69433820D1 (de) 2004-07-01
PT751781E (pt) 2004-09-30
AU680102B2 (en) 1997-07-17
WO1995017202A1 (en) 1995-06-29
NO962526L (no) 1996-08-23
ES2222463T3 (es) 2005-02-01
DK0751781T3 (da) 2004-08-09
NZ278740A (en) 1998-05-27
JPH09507074A (ja) 1997-07-15
NO320354B1 (no) 2005-11-28
EP0751781A1 (de) 1997-01-08
EP0751781B1 (de) 2004-05-26
NO962526D0 (no) 1996-06-14
EP0751781A4 (de) 1999-09-22
CA2179196A1 (en) 1995-06-29
AU1516895A (en) 1995-07-10
DE69433820T2 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
DE69433820D1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
ATE156018T1 (de) Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
DE69428268D1 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
ATE179458T1 (de) Verwendung von papillomavirusprotein l2 zur therapeutischen behandlung von durch papillomavirus hervorgerufenen tumoren oder oder anderen krankhaften veränderungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE194497T1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
ATE98869T1 (de) Pharmazeutisches mittel fuer behandlung von menschlichem krebs und verfahren zu seiner herstellung.
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
DE3776561D1 (de) Verwendung von petasites-extrakten zur herstellung eines arzneimittels zur behandlung von gastrointestinalen erkrankungen.
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69630055D1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
DE69124095D1 (de) Behandlung von männerunfruchtbarkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0751781

Country of ref document: EP

RZN Patent revoked